Appendix 4D & Half-year Financial Report December 2022
Filed with ASX · · 22 pages · English
An explanation of the key financial elements contributing to the revenue and result above can be found in the review of operations included within the Directors’ report. Distributions No dividends have been paid or declared by the Company for the current financial period. No dividends were paid for the previous financial period. Changes in controlled entities On 14 July 2022, GTG acquired Affinity
Genetic Technologies Limited on 6ix
In the deck
Story so far
Earlier from Genetic Technologies
- Receipt of R&D Tax Incentive Refund for geneType Multi Test
- Publication Highlights geneType Outperforms Current Models
- Business Update - February 2023
- Supplementary Announcement - Comprehensive Risk Test
- Genetic Technologies Announces US$5M Registered Direct Offer
Later from Genetic Technologies
- Further Study Validates geneType Breast Cancer Risk Test
- GeneType MultiTest Panel Expanded Inclusion of New Diseases
- Publication Validates geneType Prostate Cancer Risk Test
- Appendix 4C & Quarterly Activities Report - March 2023
- Publication Validates geneType for Melanoma Risk Assessment
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies